|Bid||64.15 x 1000|
|Ask||64.20 x 1800|
|Day's Range||63.60 - 66.74|
|52 Week Range||42.48 - 68.34|
|Beta (5Y Monthly)||0.71|
|PE Ratio (TTM)||18.54|
|Forward Dividend & Yield||1.80 (2.69%)|
|Ex-Dividend Date||Jan 01, 2020|
|1y Target Est||N/A|
U.S. FDA Accepts for Priority Review Bristol-Myers Squibb’s Application for Opdivo Plus Yervoy in First-Line Non-Small Cell Lung Cancer
Nektar Therapeutics and Bristol-Myers Squibb Amend Strategic Collaboration Agreement for bempegaldesleukin Plus Opdivo (nivolumab)
New England Journal of Medicine Publishes Results of Pivotal Phase 3 Reblozyl® (luspatercept-aamt) MEDALIST Trial
Bristol-Myers Squibb to Take Part at the Goldman Sachs 12th Annual Healthcare CEOs Unscripted Conference
BMS receives European Commission approval for Revlimid® (lenalidomide) in combination with rituximab for the treatment of adult patients....
BALTIMORE and PHILADELPHIA, Dec. 19, 2019 -- WindMIL Therapeutics today announced it has entered into a new clinical research collaboration with Bristol-Myers Squibb Company.
Bristol-Myers Squibb Announces Submission of Biologics License Application for CAR T-Cell Therapy Lisocabtagene Maraleucel (liso-cel) to FDA
BRISTOL-MYERS SQUIBB PRESENTS OVERALL SURVIVAL AND SAFETY DATA FROM PIVOTAL CC-486 STUDY QUAZAR AML-001
Reblozyl Studies Evaluating Treatment of Anemia in Rare Blood Diseases Presented at American Society of Hematology (ASH) Annual Meeting
Studies Evaluating Liso-Cel in Multiple Additional Patient Populations, Site of Care and Disease Areas Presented at American Society of Hematology
Findings Released from Real-World Data Analysis of Eliquis (apixaban) for the Treatment of Venous Thromboembolism in Patients with Active Cancer
BRISTOL-MYERS SQUIBB ANNOUNCES LISO-CEL MET PRIMARY AND SECONDARY ENDPOINTS IN TRANSCEND NHL 001 STUDY
BMS and bluebird bio Announce Positive Top-line Results from the Pivotal Phase 2 KarMMa Study of Ide-cel in Relapsed and Refractory Multiple Myeloma
Bristol-Myers Squibb and Acceleron Pharma Provide Update on FDA Advisory Committee for Reblozyl® (luspatercept-aamt)
Bristol-Myers Squibb Company (BMY) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for ORENCIA® (abatacept) for the prevention of moderate to severe acute graft-versus-host disease (GvHD) in hematopoietic stem cell transplants from unrelated donors. Stem cell transplants have been shown to be an effective treatment for aggressive leukemias and other hematological malignancies, often representing the only therapeutic option for cure. “While ideally we prefer using fully matched transplants from a sibling for the treatment of hematologic cancers, only the minority of patients have such a sibling,” said study lead investigator Leslie Kean, M.D., Director of the Stem Cell Transplantation Program, Dana Farber/Boston Children’s Cancer and Blood Disorders Center.
Bristol-Myers Squibb Company (BMY) and Acceleron Pharma Inc. (XLRN) today announced the U.S. Food and Drug Administration’s (FDA) Oncologic Drugs Advisory Committee will hold a review of Bristol-Myers Squibb’s supplemental Biologics License Application (sBLA) for the use of Reblozyl® (luspatercept-aamt) in patients with myelodysplastic syndromes (MDS) at its meeting on December 18, 2019. Bristol-Myers Squibb is seeking approval of Reblozyl, an erythroid maturation agent representing a new class of therapy, for the treatment of adult patients with very low- to intermediate-risk MDS-associated anemia who have ring sideroblasts and require red blood cell (RBC) transfusions.
Bristol-Myers Squibb Company (BMY) will hold an investor webcast on Sunday, December 8, 2019 at 8:00 p.m. ET to discuss data presented at the American Society of Hematology meeting, in Orlando. Company executives will provide an overview of data presented and address questions from investors and analysts. Investors and the general public are invited to listen to a live webcast of the event at investor.bms.com.
Bristol-Myers Squibb Company announced today the final results of the offers to exchange notes issued by Celgene Corporation for up to $19,850,000,000 aggregate principal amount of new notes to be issued by Bristol-Myers Squibb Company and cash and the related consent solicitations made by Bristol-Myers Squibb on behalf of Celgene to adopt certain proposed amendments to the indentures governing the ...
THOUSAND OAKS, Calif., Nov. 21, 2019 /PRNewswire/ -- Amgen (AMGN) today announced the successful completion of its acquisition of worldwide rights to Otezla® (apremilast), the only oral, non-biologic treatment for moderate-to-severe plaque psoriasis and psoriatic arthritis. Otezla was acquired from Celgene Corporation (CELG) in connection with its previously announced merger with Bristol-Myers Squibb Company (BMY), which was completed on Nov. 20. Otezla is an important treatment in the post-topical, pre-biologic segment in its approved indications in the U.S., including the treatment of patients with moderate-to-severe plaque psoriasis who are candidates for phototherapy or systemic therapy; adult patients with active psoriatic arthritis; and adult patients with oral ulcers associated with Behçet's Disease.
Bristol-Myers Squibb Company (BMY) announced today that it has completed its acquisition of Celgene Corporation (CELG) following the receipt of regulatory approval from all government authorities required by the merger agreement and, as announced on April 12, 2019, approval by Bristol-Myers Squibb and Celgene stockholders. Upon completion of the acquisition, pursuant to the terms of the merger agreement, Celgene became a wholly owned subsidiary of Bristol-Myers Squibb Company. Under the terms of the merger, Celgene shareholders received for each share, 1.00 share of Bristol-Myers Squibb common stock, $50.00 in cash without interest and one tradeable Contingent Value Right (CVR), which will entitle the holder to receive a payment of $9.00 in cash if certain future regulatory milestones are achieved.